|
Real-time
Euronext Paris
19:44:44 26/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 1.292 EUR | -2.42% |
|
+3.03% | -41.00% |
| 10-12 | Crossject: No market launch of Zepizure before H127 at best | AL |
| 09-25 | Crossject: H126. Quid novi sub sole? Not much. | AL |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Drug Delivery Systems
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 80.72M | - | - | |||
| 179B | |||||
| 118B | |||||
| 117B | |||||
| 93.26B | |||||
| 63.16B |
- Stock Market
- Stocks
- ALCJ Stock
- Charts Crossject
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
